Quizartinib

Myelodysplastic Syndrome

M.D. Anderson Cancer CenterSmall moleculePhase 2/3Active

BB

67/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 53/ 100
Competitive Position: 95/ 100

Competitive context

295 Active assets in the Myelodysplastic Syndrome cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide Sawa Ito, MD	Phase 4	BB
Nivestim City of Hope Medical Center	Phase 4	BB
Busulfanum Sawa Ito, MD	Phase 4	BB
Daunomycin OHSU Knight Cancer Institute	Phase 3	BB
Cytarabine The First Affiliated Hospital of Soochow University	Phase 4	BB

View all 50 →

Same molecule, other indications

Quizartinib is also rated in:

acute myeloid leukemia, FLT3 internal tandem duplicationDormant

BB

Indicative · Phase 2

64 / 100

acute myeloid leukemiaActive

B

Indicative · Phase 3

63 / 100

childhood acute myeloid leukemiaActive

B

Indicative · Phase 2

60 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.